Warner-lambert Company

Millennium Pharmaceuticals Limited

Other

Paul C Unangst

David T Connor

Roderick J Sorenson

Wiaczeslaw A Cetenko

Jagadish C Sircar

Charles F Schwender

Bharat Kalidas Trivedi

Elizabeth A Johnson

John S Kiely

Richard E Brown

Mary E Carethers

Larry D Bratton

Robert F Bruns

Catherine R Kostlan

Steven Robert Miller

Diane H Boschelli

Gary Frederick Filzen

Andrew G Geyer

Daniel L Flynn

Lawrence D Wise

James Bernard Kramer

Michael D Mullican

Bruce J Auerbach

Gary P Shrum

Bruce D Roth

Michael William Wilson

Stephen J Johnson

Suzanne Ross Kesten

Stephen R Stabler

David Christopher Horwell

Alexander James Bridges

Kenneth Gordon Carson

Martyn C Pritchard

Chitase Lee

Xue-min Cheng

Bradley Dean Tait

Yuntao Song

Edward Roberts

Richard John Booth

Thomas Capiris

Reginald S Richardson

Ann Holmes

Corinne E Augelli-Szafran

Julian Aranda

Arthur C Fabian

Uwe Trostmann

Hans-Jurgen Betche

Kuai-Lin Sun

Noe Erasga

Roberta Ellen Glynn

Stephen S Stabler

Sony S Khatana

Frank Fontsere

S Russell Stabler

Robert J Weikert

Wiaczeslaw A Centenko

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds of their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of suppressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Compounds that modulate PPAR activity and methods for their preparation

This invention relates to compounds that alter PPAR activity. The invention also relates to pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing dyslipidemia, hypercholesterolemia, obesity, hyperglycemia, atherosclerosis, hypertriglyceridemia and hyperinsulinemia in a mammal. The present invention also relates to methods for making the disclosed compounds.

Compounds that modulate PPAR activity and methods of preparation

The present invention relates to sulfones that are useful in the treatment of chemokine-mediated disorders. In certain embodiments, the present invention concerns the compounds that are MCP-1 receptor antagonists.

MCP-1 receptor antagonists and methods of use thereof

This invention discloses compounds that alter PPAR activity. The invention also discloses pharmaceutically acceptable salts of the compounds, pharmaceutically acceptable compositions comprising the compounds or their salts, and methods of using them as therapeutic agents for treating or preventing disipidemia, hypercholesteremia, obesity, eating disorders, hyperglycemia, atherosclerosis, hypertriglyceridemia, hyperinsulinemia and diabetes in a mammal as well as methods of supressing appetite and modulating leptin levels in a mammal. The present invention also discloses methods for making the disclosed compounds.

Aryl alkenamides derivatives as MCP-1 antagonists

The instant invention is a series of compounds which are MCP-1 receptor antagonists of Formula I

Chemokine receptor antagonists

This invention relates to compounds that are antagonists of dopamine D4 receptors, and to methods of treating psychosis and schizophrenia using a compound that is an antagonist of dopamine D4 receptors.

Method of treating psychosis and schizophrenia

Compounds and method of treating psychosis and schizophrenia

1,2,3,4-Tetrahydro-chromeno�3,4-c!pyridin-5-ones of the formula ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, and R.sub.5 include hydrogen, alkyl, alkoxy, hydroxy, halo, nitro, amino, and trifluoromethyl; R.sub.4 is unsubstituted or substituted phenyl, pyridyl, or quinolinyl; and n is 0 to 4, are useful to treat psychosis in mammals, particularly schizophrenia.

Antipsychotic method utilizing certain

Benzothiophene, benzofuran and indolethiazepinones, oxazepinones and diazepinones as well as methods of preparation thereof are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases; these compounds also inhibit the activation of human immunodeficiency virus (HIV).

Benzothiophene, benzofuran and indole-thiazepinones, oxazepinones and

The novel 3,5-ditertiarybutyl-4-hydroxy-phenylmethylene derivative of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents having inhibiting activity for 5-lipoxygenase, cyclooxygenase, or both.

3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of

Benzothiophene, benzofuran and indole-thiazepinones, oxazepinones and diazepinones as well as methods of preparation thereof are described as agents which inhibit leukocyte adherence to vascular endothelium and, as such, are effective therapeutic agents for treating inflammatory diseases.

Method for treating inflammatory disease in humans

Growing community of inventors

Ann Arbor, MI, United States of America

Paul C Unangst